Allergan warns Valeant bid would hit R&D

Allergan warns Valeant bid would hit R&D

[at Financial Times] – Allergan has launched a robust defence against a near-$50bn bid by rival drugmaker Valeant and activist investor Bill Ackman, warning that a takeover would crush research and severely impair its ability … more

View todays social media effects on BAC

View the latest stocks trending across Twitter. Click to view dashboard

See who Bank is hiring next, click here to view

Share this post